{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:54:48Z","timestamp":1789674888675,"version":"4.0.1"},"reference-count":83,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100011094","name":"Public Health Agency of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011094","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","cell.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.molmed.2017.07.002","type":"journal-article","created":{"date-parts":[[2017,8,17]],"date-time":"2017-08-17T00:30:29Z","timestamp":1502929829000},"page":"820-830","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Clinical Evaluation of Ebola Virus Disease Therapeutics"],"prefix":"10.1016","volume":"23","author":[{"given":"Guodong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhai","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Plummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George F.","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Kobinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangguo","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2017.07.002_bib0005","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1146\/annurev-pathol-052016-100506","article-title":"The pathogenesis of Ebola virus disease","volume":"12","author":"Baseler","year":"2017","journal-title":"Ann. Rev. Pathol"},{"key":"10.1016\/j.molmed.2017.07.002_bib0010","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1513\/AnnalsATS.201410-481PS","article-title":"Clinical presentation and management of severe Ebola virus disease","volume":"11","author":"West","year":"2014","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.molmed.2017.07.002_bib0015","article-title":"Ebola RNA persistence in semen of Ebola virus disease survivors \u2013 preliminary report","author":"Deen","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2017.07.002_bib0020","doi-asserted-by":"crossref","first-page":"e008859","DOI":"10.1136\/bmjopen-2015-008859","article-title":"Systematic review of the literature on viral persistence and sexual transmission from recovered Ebola survivors: evidence and recommendations","volume":"6","author":"Thorson","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.molmed.2017.07.002_bib0025","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nrmicro3524","article-title":"Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus","volume":"13","author":"Messaoudi","year":"2015","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.molmed.2017.07.002_bib0030","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.cell.2014.10.006","article-title":"Camouflage and misdirection: the full-on assault of ebola virus disease","volume":"159","author":"Misasi","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2017.07.002_bib0035","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.biocel.2005.02.018","article-title":"Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever","volume":"37","author":"Bray","year":"2005","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.molmed.2017.07.002_bib0040","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00281-017-0637-x","article-title":"Molecular pathogenesis of viral hemorrhagic fever","volume":"39","author":"Basler","year":"2017","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.molmed.2017.07.002_bib0045","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/cdd.2015.67","article-title":"Molecular mechanisms of Ebola virus pathogenesis: focus on cell death","volume":"22","author":"Falasca","year":"2015","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.molmed.2017.07.002_bib0050","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1086\/379199","article-title":"Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation","volume":"188","author":"Bosio","year":"2003","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.molmed.2017.07.002_bib0055","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.4049\/jimmunol.170.6.2797","article-title":"Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses","volume":"170","author":"Mahanty","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2017.07.002_bib0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000837","article-title":"Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis","volume":"4","author":"Wauquier","year":"2010","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.molmed.2017.07.002_bib0065","doi-asserted-by":"crossref","first-page":"4058","DOI":"10.4049\/jimmunol.180.6.4058","article-title":"Functional CD8+ T cell responses in lethal Ebola virus infection","volume":"180","author":"Bradfute","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2017.07.002_bib0070","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1073\/pnas.1502619112","article-title":"Human Ebola virus infection results in substantial immune activation","volume":"112","author":"McElroy","year":"2015","journal-title":"Proc Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2017.07.002_bib0075","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1146\/annurev-pharmtox-010716-105055","article-title":"Will there be a cure for Ebola?","volume":"57","author":"Cardile","year":"2017","journal-title":"Ann. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.molmed.2017.07.002_bib0080","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.drudis.2014.12.010","article-title":"Small molecule inhibitors of ebola virus infection","volume":"20","author":"Picazo","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.molmed.2017.07.002_bib0085","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1128\/AAC.01074-08","article-title":"Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106","volume":"53","author":"Julander","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.molmed.2017.07.002_bib0090","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1128\/AAC.46.4.977-981.2002","article-title":"In vitro and in vivo activities of anti-influenza virus compound T-705","volume":"46","author":"Furuta","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.molmed.2017.07.002_bib0095","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","article-title":"Mechanism of action of T-705 against influenza virus","volume":"49","author":"Furuta","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.molmed.2017.07.002_bib0100","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1073\/pnas.0909603107","article-title":"T-705 (favipiravir) activity against lethal H5N1 influenza A viruses","volume":"107","author":"Kiso","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2017.07.002_bib0105","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1128\/AAC.01739-09","article-title":"In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses","volume":"54","author":"Sleeman","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.molmed.2017.07.002_bib0110","doi-asserted-by":"crossref","first-page":"e2790","DOI":"10.1371\/journal.pntd.0002790","article-title":"Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley Fever","volume":"8","author":"Caroline","year":"2014","journal-title":"PLoS Negl. Trop. Dis"},{"key":"10.1016\/j.molmed.2017.07.002_bib0115","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.antiviral.2008.07.009","article-title":"Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents","volume":"80","author":"Morrey","year":"2008","journal-title":"Antivir. Res."},{"key":"10.1016\/j.molmed.2017.07.002_bib0120","doi-asserted-by":"crossref","first-page":"e2804","DOI":"10.1371\/journal.pntd.0002804","article-title":"Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever","volume":"8","author":"Oestereich","year":"2014","journal-title":"PLoS Negl. Trop. Dis"},{"key":"10.1016\/j.molmed.2017.07.002_bib0125","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2014.01.016","article-title":"Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment","volume":"104","author":"Scharton","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.molmed.2017.07.002_bib0130","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.antiviral.2014.02.014","article-title":"Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model","volume":"105","author":"Oestereich","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.molmed.2017.07.002_bib0135","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.antiviral.2014.01.012","article-title":"Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model","volume":"104","author":"Smither","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.molmed.2017.07.002_bib0140","doi-asserted-by":"crossref","first-page":"e1001967","DOI":"10.1371\/journal.pmed.1001967","article-title":"Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea","volume":"13","author":"Sissoko","year":"2016","journal-title":"PLoS Med."},{"key":"10.1016\/j.molmed.2017.07.002_bib0145","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/cid\/ciw571","article-title":"Clinical and virological characteristics of Ebola virus disease patients treated with favipiravir (T-705) \u2013 Sierra Leone, 2014","volume":"63","author":"Bai","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.molmed.2017.07.002_bib0150","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.antiviral.2015.08.015","article-title":"Ebola virus dynamics in mice treated with favipiravir","volume":"123","author":"Madelain","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.molmed.2017.07.002_bib0155","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1473-3099(14)71047-3","article-title":"Dose regimen of favipiravir for Ebola virus disease","volume":"15","author":"Mentre","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.molmed.2017.07.002_bib0160","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa1411680","article-title":"Clinical illness and outcomes in patients with Ebola in Sierra Leone","volume":"371","author":"Schieffelin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2017.07.002_bib0165","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1056\/NEJMoa1411249","article-title":"Clinical presentation of patients with Ebola virus disease in Conakry, Guinea","volume":"372","author":"Bah","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2017.07.002_bib0170","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1172\/JCI83162","article-title":"Ebola viral load at diagnosis associates with patient outcome and outbreak evolution","volume":"125","author":"de La Vega","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"Suppl 3","key":"10.1016\/j.molmed.2017.07.002_bib0175","doi-asserted-by":"crossref","first-page":"S810","DOI":"10.1093\/infdis\/jir299","article-title":"Basic clinical and laboratory features of filoviral hemorrhagic fever","volume":"204","author":"Kortepeter","year":"2011","journal-title":"J. Infect. Dis."},{"issue":"Suppl 2","key":"10.1016\/j.molmed.2017.07.002_bib0180","doi-asserted-by":"crossref","first-page":"S364","DOI":"10.1086\/520613","article-title":"Blood chemistry measurements and D-Dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus","volume":"196","author":"Rollin","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.molmed.2017.07.002_bib0185","doi-asserted-by":"crossref","first-page":"e0005389","DOI":"10.1371\/journal.pntd.0005389","article-title":"Favipiravir pharmacokinetics in Ebola-infected patients of the JIKI trial reveals concentrations lower than targeted","volume":"11","author":"Nguyen","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.molmed.2017.07.002_bib0190","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1099\/0022-1317-80-2-355","article-title":"Characterization of the L gene and 5\u2032 trailer region of Ebola virus","volume":"80","author":"Volchkov","year":"1999","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.molmed.2017.07.002_bib0195","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(10)60357-1","article-title":"Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study","volume":"375","author":"Geisbert","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2017.07.002_bib0200","doi-asserted-by":"crossref","first-page":"e1001997","DOI":"10.1371\/journal.pmed.1001997","article-title":"Experimental treatment of Ebola virus disease with TKM-130803: a single-arm phase 2 clinical trial","volume":"13","author":"Dunning","year":"2016","journal-title":"PLoS Med."},{"key":"10.1016\/j.molmed.2017.07.002_bib0205","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M15-0530","article-title":"Characteristics and clinical management of a cluster of 3 patients with Ebola virus disease, including the first domestically acquired cases in the United States","volume":"163","author":"Liddell","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.molmed.2017.07.002_bib0210","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/cid\/civ334","article-title":"The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States","volume":"61","author":"Kraft","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.molmed.2017.07.002_bib0215","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nature14442","article-title":"Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates","volume":"521","author":"Thi","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2017.07.002_bib0220","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1128\/JVI.78.8.4330-4341.2004","article-title":"Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome","volume":"78","author":"Towner","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.molmed.2017.07.002_bib0225","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.3201\/eid2209.151621","article-title":"Clinical features of and risk factors for fatal Ebola virus disease, Moyamba District, Sierra Leone, December 2014-February 2015","volume":"22","author":"Haaskjold","year":"2016","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.molmed.2017.07.002_bib0230","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/S0140-6736(14)62384-9","article-title":"Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care","volume":"385","author":"Wolf","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2017.07.002_bib0235","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrg3978","article-title":"Knocking down disease: a progress report on siRNA therapeutics","volume":"16","author":"Wittrup","year":"2015","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.molmed.2017.07.002_bib0240","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1128\/JVI.01160-10","article-title":"Ebolavirus proteins suppress the effects of small interfering RNA by direct interaction with the mammalian RNA interference pathway","volume":"85","author":"Fabozzi","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.molmed.2017.07.002_bib0245","first-page":"007","article-title":"Evaluation of different strategies for post-exposure treatment of Ebola virus infection in rodents","author":"Richardson","year":"2011","journal-title":"J. Bioterror. Biodef."},{"key":"10.1016\/j.molmed.2017.07.002_bib0250","doi-asserted-by":"crossref","first-page":"e1005263","DOI":"10.1371\/journal.ppat.1005263","article-title":"Interferon-gamma inhibits Ebola virus infection","volume":"11","author":"Rhein","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.molmed.2017.07.002_bib0255","doi-asserted-by":"crossref","first-page":"7754","DOI":"10.1128\/JVI.00173-13","article-title":"Monoclonal antibodies combined with adenovirus-vectored interferon significantly extend the treatment window in Ebola virus-infected guinea pigs","volume":"87","author":"Qiu","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.molmed.2017.07.002_bib0260","doi-asserted-by":"crossref","first-page":"207ra143","DOI":"10.1126\/scitranslmed.3006605","article-title":"mAbs and Ad-vectored IFN-alpha therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms","volume":"5","author":"Qiu","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2017.07.002_bib0265","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1093\/infdis\/jis921","article-title":"Interferon-beta therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever","volume":"208","author":"Smith","year":"2013","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.molmed.2017.07.002_bib0270","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/bmj.2.6086.541","article-title":"A case of Ebola virus infection","volume":"2","author":"Emond","year":"1977","journal-title":"BMJ"},{"key":"10.1016\/j.molmed.2017.07.002_bib0275","doi-asserted-by":"crossref","first-page":"e0004364","DOI":"10.1371\/journal.pntd.0004364","article-title":"A rapid screening assay identifies monotherapy with interferon-\u03b2 and combination therapies with nucleoside analogs as effective inhibitors of Ebola virus","volume":"10","author":"McCarthy","year":"2016","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.molmed.2017.07.002_bib0280","doi-asserted-by":"crossref","first-page":"e0169255","DOI":"10.1371\/journal.pone.0169255","article-title":"Interferon beta-1a for the treatment of Ebola virus disease: a historically controlled, single-arm proof-of-concept trial","volume":"12","author":"Konde","year":"2017","journal-title":"PLoS One"},{"issue":"Suppl 1","key":"10.1016\/j.molmed.2017.07.002_bib0285","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1086\/514298","article-title":"Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee","volume":"179","author":"Mupapa","year":"1999","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.molmed.2017.07.002_bib0290","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa1511812","article-title":"Evaluation of convalescent plasma for Ebola virus disease in Guinea","volume":"374","author":"van Griensven","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2017.07.002_bib0295","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMc1609116","article-title":"Efficacy of convalescent plasma in relation to dose of Ebola virus antibodies","volume":"375","author":"van Griensven","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2017.07.002_bib0300","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.1128\/JVI.73.7.6024-6030.1999","article-title":"Ebola virus can be effectively neutralized by antibody produced in natural human infection","volume":"73","author":"Maruyama","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.molmed.2017.07.002_bib0305","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.cell.2015.12.022","article-title":"Cross-reactive and potent neutralizing antibody responses in human survivors of natural Ebolavirus infection","volume":"164","author":"Flyak","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2017.07.002_bib0310","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1126\/science.aad5788","article-title":"Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak","volume":"351","author":"Bornholdt","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.molmed.2017.07.002_bib0315","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.aad5224","article-title":"Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody","volume":"351","author":"Corti","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.molmed.2017.07.002_bib0320","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.cell.2017.04.037","article-title":"Antibodies from a human survivor define sites of vulnerability for broad protection against Ebolaviruses","volume":"169","author":"Wec","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2017.07.002_bib0325","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1126\/science.287.5458.1664","article-title":"Epitopes involved in antibody-mediated protection from Ebola virus","volume":"287","author":"Wilson","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.molmed.2017.07.002_bib0330","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1128\/JVI.77.2.1069-1074.2003","article-title":"Identification of protective epitopes on ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses","volume":"77","author":"Takada","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.molmed.2017.07.002_bib0335","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.clim.2011.08.008","article-title":"Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies","volume":"141","author":"Qiu","year":"2011","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.molmed.2017.07.002_bib0340","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1128\/JVI.02172-15","article-title":"Macaque Monoclonal antibodies targeting novel conserved epitopes within filovirus glycoprotein","volume":"90","author":"Keck","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.molmed.2017.07.002_bib0345","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.cell.2017.04.038","article-title":"Immunization-elicited broadly protective antibody reveals Ebolavirus fusion loop as a site of vulnerability","volume":"169","author":"Zhao","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2017.07.002_bib0350","doi-asserted-by":"crossref","first-page":"10982","DOI":"10.1128\/JVI.01490-15","article-title":"Mechanism of binding to Ebola virus glycoprotein by the ZMapp, ZMAb, and MB-003 cocktail antibodies","volume":"89","author":"Davidson","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.molmed.2017.07.002_bib0355","doi-asserted-by":"crossref","first-page":"199ra113","DOI":"10.1126\/scitranslmed.3006608","article-title":"Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail","volume":"5","author":"Pettitt","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2017.07.002_bib0360","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature13777","article-title":"Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp","volume":"514","author":"Qiu","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2017.07.002_bib0365","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.molmed.2015.12.005","article-title":"Progression of Ebola therapeutics during the 2014-2015 outbreak","volume":"22","author":"Mendoza","year":"2016","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.molmed.2017.07.002_bib0370","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1604330","article-title":"A randomized, controlled trial of ZMapp for Ebola virus infection","volume":"375","author":"Group","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2017.07.002_bib0375","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02227-14","article-title":"Evaluation of the potential impact of Ebola virus genomic drift on the efficacy of sequence-based candidate therapeutics","volume":"6","author":"Kugelman","year":"2015","journal-title":"MBio"},{"key":"10.1016\/j.molmed.2017.07.002_bib0380","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1093\/infdis\/jiw061","article-title":"Design of a randomized controlled trial for Ebola virus disease medical countermeasures: PREVAIL II, the Ebola MCM Study","volume":"213","author":"Dodd","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.molmed.2017.07.002_bib0385","doi-asserted-by":"crossref","first-page":"e01913","DOI":"10.1128\/JVI.01913-16","article-title":"Functional characterization of adaptive mutations during the West African Ebola virus outbreak","volume":"91","author":"Dietzel","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.molmed.2017.07.002_bib0390","doi-asserted-by":"crossref","first-page":"S281","DOI":"10.1093\/infdis\/jiw267","article-title":"Pathogenicity comparison between the Kikwit and Makona Ebola virus variants in rhesus macaques","volume":"214","author":"Wong","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.molmed.2017.07.002_bib0395","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.celrep.2016.04.026","article-title":"Antibody treatment of Ebola and Sudan virus infection via a uniquely exposed epitope within the glycoprotein receptor-binding site","volume":"15","author":"Howell","year":"2016","journal-title":"Cell Rep."},{"issue":"Suppl 2","key":"10.1016\/j.molmed.2017.07.002_bib0400","doi-asserted-by":"crossref","first-page":"S410","DOI":"10.1093\/infdis\/jiv209","article-title":"Development and characterization of broadly cross-reactive monoclonal antibodies against all known Ebolavirus species","volume":"212","author":"Hernandez","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.molmed.2017.07.002_bib0405","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1128\/JVI.02171-15","article-title":"Pan-ebolavirus and Pan-filovirus mouse monoclonal antibodies: protection against Ebola and Sudan viruses","volume":"90","author":"Holtsberg","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.molmed.2017.07.002_bib0410","doi-asserted-by":"crossref","first-page":"20514","DOI":"10.1038\/srep20514","article-title":"Discovery of an antibody for pan-ebolavirus therapy","volume":"6","author":"Furuyama","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2017.07.002_bib0415","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s13238-015-0231-8","article-title":"Can Ebola virus become endemic in the human population?","volume":"7","author":"Wong","year":"2016","journal-title":"Protein Cell"}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491417301090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491417301090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T08:26:12Z","timestamp":1602750372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491417301090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":83,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S1471491417301090"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2017.07.002","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Evaluation of Ebola Virus Disease Therapeutics","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2017.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}